MedPath

Clinical Trial News

Four Key Drivers Reshaping Successful Oncology Drug Launches in Modern Market

  • The oncology market is experiencing significant transformation, with growth rates slowing despite remaining the top therapy area, requiring new strategic approaches for successful drug launches.
  • Companies must focus on optimal indication sequencing, patient segmentation through biomarkers, and novel payer acceptance strategies to navigate increasingly restrictive market access.
  • Building a strong oncology franchise through long-term commitment, engagement with key opinion leaders, and strategic clinical trial planning is crucial for commercial success.

FDA Approves Lialda for Maintenance of Remission in Ulcerative Colitis Patients

The U.S. Food and Drug Administration (FDA) has approved Shire plc's Lialda (mesalamine) Delayed Release Tablets for the maintenance of remission in patients with ulcerative colitis, following a six-month study demonstrating its safety and effectiveness. This approval adds to Lialda's previous indication for inducing remission in patients with active, mild to moderate ulcerative colitis.

Metallic Copper as an Antimicrobial Surface: A Comprehensive Review

This article reviews the antimicrobial properties of metallic copper surfaces, highlighting their effectiveness in killing bacteria, yeasts, and viruses. It discusses the historical use of copper, its mechanism of action, and recent clinical trials demonstrating its potential in reducing hospital-acquired infections.

Global Pharmaceutical R&D Outsourcing Trends: Industry Shifts Toward Strategic Partnerships and Offshore Operations

  • Pharmaceutical companies are increasingly outsourcing R&D activities upstream in the value chain, including basic chemistry research and preclinical studies, driven by cost pressures and CRO capability expansion.
  • Clinical trials are becoming more globally distributed, with emerging markets in Asia and Eastern Europe gaining prominence alongside traditional US and European research centers.
  • IT-enabled R&D services face growing competition from global IT outsourcing and BPO providers, challenging traditional CROs in data management and programming services.

Urovant Sciences Launches GEMTESA® (vibegron) for Overactive Bladder Treatment in the U.S.

  • Urovant Sciences has commercially launched GEMTESA® (vibegron) 75 mg tablets in the U.S. for treating overactive bladder (OAB) symptoms in adults.
  • GEMTESA, a beta-3 adrenergic receptor agonist, is the first new oral branded OAB medication in nearly a decade, offering a novel treatment option.
  • Clinical studies demonstrated that GEMTESA significantly reduces key OAB symptoms compared to placebo, without association to cognitive decline.
  • Approximately 30 million Americans suffer from OAB, highlighting the importance of new treatments like GEMTESA to improve daily activities.

Global Economic Pressures Force Pharmaceutical Industry to Confront Radical Transformation

  • The pharmaceutical industry faces unprecedented challenges due to patent cliffs, pricing pressures, and a shift from blockbuster drugs to niche products, necessitating fundamental industry restructuring.
  • Healthcare systems, particularly in the UK and US, are implementing severe cost-cutting measures, with the NHS targeting £20bn in annual savings and US healthcare requiring $80bn reduction over 10 years.
  • Industry experts call for urgent reform of regulatory frameworks, including Good Clinical Practice guidelines and EU Clinical Trials directive, to maintain pharmaceutical innovation while managing rising development costs.

FDA Expands Access to Investigational Drugs for Treatment Use

The FDA has finalized a rule to expand access to investigational drugs for patients with serious or immediately life-threatening diseases or conditions who have no comparable or satisfactory alternative therapy. This rule aims to increase awareness and knowledge of expanded access programs, detailing criteria, submission requirements, and safeguards for different types of expanded access.

Trending News

1

Lundbeck's Eptinezumab Shows Strong Efficacy in Asian Chronic Migraine Patients in Phase III SUNRISE Trial

2 days ago
2

Lilly's Once-Weekly Insulin Efsitora Alfa Achieves Non-Inferiority in Phase 3 Trials, Reducing Injection Burden by 300 Doses Annually

a day ago
3

Japanese Startup's Urine-Based Cancer Test Detects Stage 0 Lung Cancer in Hokkaido Pilot Study

2 days ago
4

GH Research Submits IND Hold Response to FDA for Depression Treatment GH001 Ahead of Schedule

3 days ago
5

Otsuka Pharmaceutical Secures Global Rights to HBM7020 BCMAxCD3 Bispecific T-Cell Engager for Autoimmune Diseases

15 hours ago
6

CanSinoBIO Launches iPneucia® 13-Valent Pneumococcal Vaccine Optimized for Chinese Children

3 days ago
7

Novo Nordisk's Mim8 Shows Safe Direct Switch from Emicizumab in Phase 3b Hemophilia A Trial

a day ago
8

EMA Recommends Approval of Alvotech's Biosimilar to Eylea for Eye Disorders

7 hours ago
9

Roche's NXT007 Achieves Zero Bleeds in Phase I/II Hemophilia A Trial, Advances to Phase III

12 hours ago
10

GLP-1 Diabetes Drug Liraglutide Reduces Migraine Days by Half in Pilot Study

3 days ago
Subscribe Icon

Daily Pharma Insights

Get curated, high-impact pharmaceutical news delivered to your inbox every morning.

  • Critical clinical trial updates & results
  • Regulatory approvals & strategic partnerships
  • Market access decisions & commercial developments
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy